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Abstract
Coarctation of the aorta was once viewed as a simple discrete narrowing of the aortic isthmus
that could be ‘cured’ by surgical intervention. It is now clear that this condition may: (1) affect
the aortic arch in a highly variable manner; (2) be associated with a host of other left sided
heart lesions; (3) represent a wider vasculopathy within the pre-coarctation arterial tree,
leading to significant prevalence of hypertension by adolescence, and subsequent risk of early
morbidity and death. This review outlines the evaluation and treatment of this disease from
pre-natal to adult life. (Cardiol J 2011; 18, 5: 487–495)
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Introduction
Coarctation of the aorta (CoA) is the fifth most
common congenital heart defect, accounting for
6–8% of live births with congenital heart disease,
with an estimated incidence of 1 in 2,500 births [1–3].
It is likely that the incidence is higher in stillborn
babies [4]. It affects more male babies than female,
with a reported ratio in males of between 1.27:1 and
1.74:1 [5, 6]. It usually manifests as a discrete con-
striction of the aortic isthmus (Fig. 1). However, it
is more likely to represent a spectrum of aortic nar-
rowing from this discrete entity to tubular hypopla-
sia, with many variations seen in between these two
extremes. Morphologists argue that tubular hypopla-
sia, although it may coexist with discrete coarctation,
should be considered as a separate entity [1] although
this has not been proven. The presence of associa-
ted arch hypoplasia is relevant to longer term risk
for the development of hypertension.
Figure 1. Magnetic resonance image of ten month-old
male infant with discrete coarctation of the aorta.
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Etiology
The etiology of the discrete isthmic constric-
tion of the aorta seen in patients with CoA remains
very much in dispute. Although familial cases have
been reported [7, 8] and association with various
gene deletions described [9], there is no experimen-
tal evidence to support a unifying theory, something
not helped by the absence of naturally occurring
animal models.
Developmental theories have focused on ab-
normalities of blood flow [10], abnormal migration
patterns of the developing aortic arch, and exces-
sive distribution of arterial duct-like tissue around
the aortic isthmus [11]. Such singular mechanistic
views do not reflect the widespread changes seen
both in left heart structures (mitral valve abnorma-
lities, bicuspid aortic valve) and upper body vascu-
lar structure (cerebral aneurysms) so commonly
associated with CoA. Peterson et al. [9] have de-
monstrated that changes induced by a gridlock muta-
tion in the hey2 gene in the zebrafish lead to chang-
es mimicking CoA in this species. Interestingly,
inducing upregulation of vascular endothelial
growth factor (VEGF) early in development is suf-
ficient to suppress the gridlock phenotype and aor-
tic abnormality in this model. VEGF plays a vital
role in aortic development, acting as a chemo-at-
tractant, stimulating angioblast migration toward
the midline before formation of the aorta [12]. In-
deed, targeted disruption of VEGF in mice leads to
significant disruption of the developing aorta [13].
VEGF is also involved in stimulating generalized
arterial differentiation through its effect on angio-
blast migration. Whether an initial mutation leads
to secondary effects on VEGF or on other signa-
ling systems involved in recruiting mural cells in
fetuses, leading to CoA, is unknown.
However, a more widespread vascular abnor-
mality might be expected if this were so, and nu-
merous studies have demonstrated normal lower
limb vascular structure and function both before and
after early coarctation repair [14–16]. The regional
vasculopathy in patients with CoA is therefore more
likely to be due to an effect of abnormal hemody-
namics as a consequence of isthmic narrowing. But
whether this is in response to reduced upper body
flow dynamics or to increased intra-arterial pres-
sure load is unclear. An increase in collagen and
decrease in smooth muscle content of the pre-co-
arctation aorta in humans has been demonstrated
in comparison to post-coarctation aorta or to proxi-
mal aorta of young transplant donors [17]. This is
consistent with a rabbit model of CoA, where in-
creased gene expression for collagen types I and III
has been demonstrated in the aorta proximal to the
coarctation site [18]. These investigators postulat-
ed that the mechanical stress associated with in-
creased pressure load may initiate rapid gene ex-
pression for collagen production, leading to re-en-
forcement and reorganization of the vessel
musculo-elastic fascicle, and thereby reducing the
degree of pressure-induced aortic dilatation. How-
ever, a clear disadvantage of this is that the result-
ant stiffer vessel will lead to augmented central
aortic systolic pressure and systolic hypertension
[19], which is the major cause of longer term mor-
bidity and mortality in these patients, even despite
early repair.
Fetal diagnosis
CoA is notoriously difficult to diagnose in fetal
life because the life-preserving presence of the ar-
terial duct makes it difficult to detect isthmal nar-
rowing. Recent reports have concentrated on se-
rial measurements of isthmal z scores and isthmal-
-to-ductal ratios by fetal echocardiography which
may be more sensitive indicators of fetal coarcta-
tion [20].
Abnormal isthmal flow patterns may also im-
prove diagnostic specificity and may reduce false
positives; however, confirmatory echocardiography
is still necessary following birth, and coarctation in
this setting cannot be ruled out completely until the
arterial duct has closed. One early, but non-speci-
fic, finding on fetal echocardiography of potential
aortic coarctation is an imbalance in ventricular size,
with right ventricular dominance [21]. This is like-
ly due to increased left ventricular diastolic pres-
sures secondary to the coarctation, reduced right-
to-left flow across the foramen ovale, and an in-
creased volume load to the right ventricle. It is
possible that these flow abnormalities may have
a long-term effect on ventricular development and
function. For example, in fetal sheep, an increase
in the load on the heart leads to an increase in the
number of binucleated myocardial cells [22], which
unlike their mononuclear counterparts are not able
to divide. Although this has implications for the to-
tal number of myocardial cells in the heart, it also
may influence how the heart will respond to pres-
sure load in the future [23]. Numerous studies have
demonstrated increased ventricular mass in normo-
tensive coarctectomy patients associated with
changes in aortic arch morphology [24, 25]. A re-
cent report showed that increased ventricular sys-
tolic stiffness, coupled with arterial stiffness, may
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be implicated in hypertension in post-coarctectomy
patients [26]. Thus, abnormalities in ventricular
development may be important in the hypertensive
response.
Presentation and management
The majority of patients affected present in
infancy with varying degrees of heart failure which
reflect predominantly the severity of the aortic nar-
rowing. Ultimately, these patients require interven-
tion; surgery is the treatment of choice in this age
group, although balloon angioplasty has been used
as a bridge to surgery in critically ill infants [27].
Early recognition is paramount, because rapid de-
terioration may occur with closure of the arterial
duct and there is a trend towards less favorable
outcomes in sicker pre-operative infants [28]. In
either case, intensive management is required to
ensure ventricular function is optimal prior to sur-
gery. Various surgical approaches have been used,
with the two commonest recent approaches being
surgical excision of the coarctation with end-to-end
anastomosis or augmentation of the coarcted aorta
using the subclavian artery, the so-called ‘subcla-
vian flap repair’ (SFR). Although reports are con-
flicting on the longer term outcomes of these two
surgical approaches, most have concentrated on
survival, the need for re-intervention and aneurysm
formation [29, 30]. Aneurysm formation is a parti-
cular concern: untreated, it can lead to rates of rup-
ture of up to 100% within 15 years [31]. Both aneu-
rysm formation and restenosis are thought to be com-
moner with SFR [32], although surgical experience
with the technique may be a factor. A recent report
indicated that SFR may be associated with abnormal
upper limb compliance and subsequent hypertension
independent of recurrent narrowing [33]. Although
this approach is less often performed in modern
practice due to the reasons discussed above, this out-
come is of significant importance in the longer term
follow-up of these patients.
Catheter intervention
Some patients may not present with CoA until
later childhood or adolescence, either due to less
severe initial narrowing or to the development of
collateral circulation bypassing the coarctation, or
both. Most of these patients present with upper
body hypertension. Non-surgical approaches to CoA
in this population became popular with the advent
of balloon angioplasty. Balloon angioplasty for co-
arctation was first reported in 1982, with use hav-
ing become widespread over the past two decades
[34]. Medium term outcome studies of balloon an-
gioplasty have shown good initial relief of stenosis,
but high rates of re-coarctation and aneurysm for-
mation [35–38].
Hence, stent implantation is now the preferred
intervention for coarctation in older children and
adults, with persistent relief of stenosis and lower
incidence of aneurysm formation compared to bal-
loon angioplasty alone [39, 40] (Fig. 2). Recent
guidelines have been published for transcatheter
treatment of both primary and recurrent coarcta-
tion (Table 1). Ballooning and/or stenting are indi-
cated when there is a transcoarctation gradient of
> 20 mm Hg at the time of catheterization, although
intervention may be warranted with less severe
gradients if there is systemic hypertension with
anatomic narrowing that may be contributing to the
hypertension [41].
Stent technology has evolved in recent years
and includes primarily balloon expanding, and oc-
casionally self-expanding, stents in addition to ex-
panded polytetrafluoroethylene covered stents.
Covered stents have also been used to treat increa-
singly complex aortic arch obstructions and aneu-
rysm formation [42, 43]. Covered stents offer the
advantage of excluding any stretch-induced wall
trauma from the endoluminal aspect of the aorta,
particularly in the catastrophic event of aortic rup-
ture which has been reported [44]. These stents are
not currently approved for use in patients with CoA
in the USA and therefore novel approaches of ap-
plying a Gore-Tex covering to a bare metal stent
have been reported to counter this [45].
The short-term efficacy of stent implantation
is well recognized but accurate long-term follow-
up assessment is sparse.  Recent reports have de-
monstrated potential physiological benefits following
stenting, including mid-term left ventricular mass
regression and long-axis function improvement, as
well as amelioration in central aortic function with
associated reduction of daytime ambulatory systolic
blood pressure [46, 47]. Long-term evaluation of
both stent and aortic wall integrity is essential to
monitor potentially life-threatening complications.
Follow-up with computed tomography examination
suggests that the overall aneurysm rate is low [48] al-
though other reports have had variable results [49, 50].
Outcomes: Don’t forget
the blood pressure!
Untreated CoA has significant early mortality,
with one report identifying CoA in 17% of neonates
490
Cardiology Journal 2011, Vol. 18, No. 5
www.cardiologyjournal.org
dying from congenital heart disease [51]. Most of
those who survive infancy reach adulthood, but the
mean age of death has been reported to be as low
as 31 years for those surviving the first year with-
out an operation [52]. Even in the treated popula-
tion, there is significant early morbidity and mor-
tality, with Cohen at al. [53] reporting estimated
mortality of almost 30% at 30 years following repair,
with an average age of death of 38 years (Fig. 3).
These outcomes are substantiated by other
studies [54–56] with Clarkson et al. [54], reporting
on 160 patients with 10–28 years of follow-up,
observing that only 20% of patients were alive with-
out complications and with a normal blood pressure
at 25 years follow-up.
To some extent, these are historical reports.
The identification and treatment outcomes of pa-
tients with congenital heart disease have improved
significantly over the past two decades  [57, 58], and
early to mid-term outcomes for patients with CoA
are excellent, with early mortality rates as low as
2% [59]. Significant longer-term morbidity remains
however, with more recent reports observing less
than 50% of patients with normal blood pressure
Figure 2. Series of images outlining stenting of a tight native coarctation with a self-fabricated covered stent in a nine
year-old male; A, B. Demonstrate AP and lateral angiographic images of the tight native coarctation with multiple
collateral arteries seen; C. Self-fabricated covered stent mounted on a balloon catheter as previously described [45];
D. Following implantation of the stent, there is no residual waist seen with no evidence of aneurysm formation. Large
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1–27 years following CoA repair [60]. The average age
at operation of this cohort was nine years and there
is emerging data to suggest that earlier age at sur-
gery may be protective against the development of
hypertension [61–63]. Although early surgery may
prevent or delay the onset of hypertension, approxi-
mately 30% of children will be hypertensive by
adolescence despite early surgery [62], and it is now
arguable that hypertension is the single most im-
portant outcome variable in patients with repaired
CoA. Most studies report resting blood pressure,
and it is well accepted that a significant number of
patients with normal resting blood pressure in the
setting of CoA have an exaggerated blood pressure
response to exercise which may predict the onset
of established hypertension [65, 66].
The causes of hypertension in this cohort of
patients are not fully understood, but malfunction
in a number of individual systems have been impli-
cated, including imbalance within the autonomic
nervous system [17, 67], impaired vascular function
[68, 69] and hyperactivation of the rennin–angio-
tensin system [70, 71]. It is likely that more than
one of these systems is involved. The effect of ab-
normal arterial compliance on the arterial barore-
ceptors located in the aortic arch and the carotid
arteries is of particular interest. Initial evidence for
links between abnormal arterial structure and
baroreceptor functioning was suggested by Sehest-
ed et al. [17]. They examined freshly resected co-
arctation tissue and demonstrated reduced isomet-
ric tension induced by potassium, noradrenaline and
Table 1. American Heart Association guidelines for catheter intervention for coarctation of the aorta [41].
Recommendations for transcatheter balloon angioplasty of coarctation/recoarctation of the aorta
Class I
1. Transcatheter systolic coarctation gradient of > 20 mm Hg and suitable anatomy, irrespective of patient age
(level of evidence: C).
2. Transcatheter systolic coarctation gradient of < 20 mm Hg in the presence of significant collateral vessels
and suitable angiographic anatomy, irrespective of patient age, as well as in patients with univentricular heart
or with significant ventricular dysfunction (level of evidence: C).
Class IIa
1. As a palliative measure to stabilize a patient when extenuating circumstances are present, such as severely
depressed ventricular function, severe mitral regurgitation, low cardiac output, or systemic disease affected
by the cardiac condition (level of evidence: C).
Class IIb
1. Beyond four to six months of age when associated with a transcatheter systolic coarctation gradient
> 20 mm Hg and suitable anatomy (level of evidence: C).
2. Native or recurrent coarctation of the aorta in patients with complex coarctation anatomy or systemic
conditions such as connective tissue disease or Turner syndrome but should be scrutinized on
a case-by-case basis (level of evidence: C).
Recommendations for stent placement in native coarctation and recoarctation of the aorta
Class I
1. Recurrent coarctation patients of sufficient size for safe stent placement, in whom the stent can be expanded
to an adult size, and who have a transcatheter systolic coarctation gradient > 20 mm Hg (level of evidence: B).
Class IIa
1. Transcatheter systolic coarctation gradient of > 20 mm Hg (level of evidence: B).
• Transcatheter systolic coarctation gradient of < 20 mm Hg but with systemic hypertension associated with
an anatomic narrowing that explains the hypertension (level of evidence: C).
• Long-segment coarctation with a transcatheter systolic coarctation gradient > 20 mm Hg (level of evidence: B).
2. When balloon angioplasty has failed, as long as a stent that can be expanded to an adult size can be
implanted (level of evidence: B).
Class IIb
1. In infants and neonates when complex aortic arch obstruction exists despite surgical or catheter-mediated
attempts to relieve this obstruction and when further surgery is regarded as high risk (level of evidence: C).
2. Transcoarctation gradient of < 20 mm Hg but with an elevated left ventricular end-diastolic pressure and an
anatomic narrowing (level of evidence: C).
• Transcoarctation gradient of < 20 mm Hg but in whom significant aortic collaterals exist, which results in an
underestimation of the coarctation (level of evidence: C).
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prostaglandin in the prestenotic aortic tissue com-
pared to the poststenotic area, indicating reduced
contractility of the prestenotic aorta. This was as-
sociated with increased collagen and reduced
smooth muscle content of the prestenotic aortic
wall. The authors postulated that aortic arch barore-
ceptors in this prestenotic area may be activated
less at a given pressure than receptors placed in
a vessel with normal distensibility, thus allowing
a higher pressure to be tolerated by the cardiac
baroreflex. This inter-relationship between reduced
arterial compliance and baroreceptor sensitivity has
been evaluated in adolescents following early CoA
repair with and without hypertension, with the re-
ported finding that stiffer central arteries may be
initially compensated for by increased barorecep-
tor sensitivity [72]. When this mechanism fails,
hypertension becomes manifest; but a timing be-
yond which this outcome becomes inevitable has
yet to be identified. Blunted baroreceptor sensiti-
vity and reduced heart rate variability have been
demonstrated in pre-operative neonates with CoA
compared to controls, suggesting early maladaptive
autonomic control of blood pressure [73].
Similar studies have been carried out in neo-
nates looking at aortic compliance in order to exa-
mine the effects of CoA on fetal and early neona-
tal arterial stiffness. Vogt et al. [15] measured local
arterial stiffness indices and distensibility in the
ascending and descending aortas of pre- and post-
operative CoA neonates, and compared these va-
lues to matched controls, demonstrating significant-
ly reduced distensibility and increased stiffness in-
dices in the ascending aortas of the pre- and
post-operative group. There was no difference in
the elastic properties of the descending aorta be-
tween the two groups. The same group was pro-
spectively re-evaluated at three years of age and
aortic elastic properties were measured in a simi-
lar fashion [16]. Persisting impairment of the local
elastic properties of the ascending aorta was noted
in the CoA group when compared to controls, al-
though correlation between these findings and the
longer term risk of hypertension was not possible.
The future
Although early outcomes are excellent, the
potential for significant longer term morbidity in
patients with CoA persists, irrespective of the ini-
tial treatment strategy. The first approach must be
wider identification of the problem. Hypertension
may be present in young children: this is often un-
der-recognized or not treated aggressively enough
[74]. More standardized protocols for the evalua-
tion of blood pressure are required, with a consen-
sus reached as to when to intervene and how to
respond to exercise-induced hypertension which is
not uncommon in adolescents and may be predic-
tive of established hypertension. Follow-up imag-
ing should be tailored towards early identification
of re-stenosis and aggressive subsequent manage-
ment. Magnetic resonance imaging has been iden-
tified as the most cost-effective means of follow-up
in older patients [75] and offers detailed images of
the aortic arch. Neuro-imaging to evaluate cerebral
aneurysms, which have been reported in 10% of
patients with CoA, may also be performed at the
same time [76]. Current recommendations to inter-
vene for re-coarctation are usually based on a sys-
tolic gradient of > 20 mm Hg at the time of cathe-
terization, although less severe gradients may be-
come more significant with provocation and it is not
yet clear how to deal with these.
Ongoing attempts to delineate the exact type
and timing of developmental maladaption that may
be responsible for the development of hypertension
are necessary to determine appropriate medical
treatment. Much controversy exists regarding the
best medical therapy for established hypertension
in these patients. In many centers, beta-blockers
are used and there is published data demonstrating
Figure 3. Taken from Cohen et al. [53]. Observed survi-
val curves to 30 years of 588 surgically treated patients
(solid line) and the expected survivorship of an age-
and sex-matched population based on cohort life ta-
bles (dashed line).
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a beneficial effect of these agents on the early post-
operative hypertensive response [77]. Recent data
has also suggested that metoprolol is more effec-
tive than candesartan at reducing arterial blood
pressure in patients with repaired CoA with vary-
ing impacts of these medications on neurohumoral
activity and vascular stiffness [78]. A recent report
demonstrated that ramipril decreases the expres-
sion of pro-inflammatory cytokines in normotensive
patients with CoA [79]. Use of agents with anti-in-
flammatory effects may be prudent, as the endo-
thelial dysfunction seen in patients with CoA may
be a consequence of inflammation driven by abnor-
mal flow dynamics at the repair site, or as a conse-
quence of a more widespread vasculopathy as part
of the ‘syndrome’ of CoA.
A more important question is whether the
course of changes in blood pressure can be altered
with early treatment. Early surgical intervention
reduces the incidence of hypertension on follow-up,
but whether or not this merely delays onset is not
yet clear. It is conceivable that early ‘prophylactic’
treatment with targeted anti-hypertensive agents
may prevent irreversible changes driving the hy-
pertensive response from occurring, and thus im-
prove the longer term outlook for these patients.
Conclusions
Although advances in the recognition and treat-
ment of patients with CoA have taken place, much work
still remains to be done to ensure that longer term
morbidity, secondary to early onset hypertension, is
minimized. CoA should be considered a lifelong disease
affecting the entire pre-coarctation arterial tree, and
regular follow-up with aggressive management of re-
coarctation is vital. Consensus guidelines drafted
from outcome data from multi-institutional networks
may provide a more consolidated approach.
In the future, further research into the mecha-
nisms driving the hypertensive response may iden-
tify therapies to target the vasculopathic changes
seen with CoA and improve these outcomes.
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